Pharmaceuticals: CHMP: MS treatments in the heart of recommendations

News published on March Monday 25, 2013
Share on
Last Friday, two multiple sclerosis drugs were recommended by the CHMP for approval: Aubagio from Sanofi and Tecfidera (BG612) from Biogen. The landscape of MS drugs completely moves from subcutaneous treatments (IFN) to oral treatments. These two drugs come on the European market in direct competition with interferons such as Rebif from Merck but also with Gilenya the first oral compound in this pathology.

Full report available to subscribers
Please contact   

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities